

21 August 2026

ASX Announcement

Second manufacturing campaign of GMP grade Galidesivir commissioned to strengthen active outbreak and biodefence inventory

- **Additional production of GMP-grade Galidesivir commissioned with PI Health Sciences to materially increase available drug inventory**
- **Following completion of manufacturing, expected in Q4 CY26, Island will have up to ~800 treatment courses available**
- **Expanded inventory provides significant supply of GMP-grade Galidesivir to support active outbreak response and broader biodefence opportunities**
- **Additional GMP-grade Galidesivir comes as ongoing Bundibugyo outbreak continues to spread rapidly across Central Africa**
- **Current outbreak has 5,208 confirmed cases and 2,476 deaths at 18 August 2026 with a case-fatality rate of 47.5%ⁱ**
- **Based on its current pace, the ongoing Bundibugyo outbreak is spreading at five times faster than previous outbreaks at the same stageⁱⁱ**
- **Galidesivir expected to be deployed in Uganda during CY26, providing opportunity to generate human efficacy, safety and virological data during an active outbreak**

MELBOURNE Australia, 21 August 2026: Australian antiviral drug development and biodefence company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to advise it has commissioned an additional production campaign of GMP-grade Galidesivir with global contract research, development and manufacturing organisation PI Health Sciences (PIHS).

The second campaign will materially expand the Company's available supply of Galidesivir for active outbreak response and broader biodefence opportunities. Following completion of the manufacturing campaign, together with previously commissioned supply, the Company expects to have approximately 700 to 800 treatment courses of Galidesivir available in Q4 CY26.

The decision to increase manufacturing represents an important strategic step for Island's Galidesivir program, providing the Company with a considerable inventory of GMP-grade drug that has the potential to be used during active outbreaks, to support engagement with government and biodefence agencies, potential procurement opportunities and ongoing regulatory engagement initiatives.

The additional commissioning follows the Company's initial engagement with PIHS (refer ASX announcement: 4 June 2026), as well as the Company's opportunity to provide Galidesivir on a compassionate use basis in patients infected with Bundibugyo Ebola virus in Uganda under the World Health Organization (WHO) recognised Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework (refer ASX announcement: 7 July 2026).

The Company's Uganda program provides an opportunity to deploy Galidesivir during an active Ebola outbreak and potentially generate prospective human efficacy, safety



and virological data. This directly complements the Company's existing pathway for potential approval for use in Marburg under the FDA's Animal rule.

The importance of maintaining a meaningful inventory of GMP-grade Galidesivir has increased as the current Bundibugyo Ebola outbreak has continued to spread rapidly across The Democratic Republic of Congo and associated countries, including Uganda. As at 18 August 2026, 5,208 confirmed cases and 2,476 deaths have now been reported giving the outbreak a case-fatality rate of 47.5% and making it one of the most significant Ebola epidemics on record. The Bundibugyo strain currently has no approved therapeutic treatment or vaccine.

Against this backdrop, Island believes establishing a substantial inventory of GMP-grade Galidesivir provides an important strategic advantage. Rather than manufacturing solely to meet the requirements of individual studies, the Company is building a supply position capable of supporting its existing development programs while providing flexibility to respond rapidly to outbreak, biodefence and government opportunities as they arise.

Management commentary:

CEO and Managing Director, Dr David Foster said: *"The decision to commission additional GMP Galidesivir reflects the significant progress we've made and the increasing breadth of opportunities now available to the program."*

"Before the end of CY26, we expect to have around 700–800 treatment courses available. This represents a considerable strategic inventory and importantly gives us the ability to pursue opportunities without having to commence a new manufacturing campaign each time a potential requirement emerges."

"The situation in Africa demonstrates why this capability matters. The current Bundibugyo Ebola outbreak is spreading rapidly and has resulted in thousands of confirmed infections and deaths. Having secured the necessary approvals to deploy Galidesivir in Uganda, we are now in a position where access to GMP-grade drug can allow us to respond to an active outbreak while potentially generating important human data for the program."

"Our strategy, however, extends beyond any single outbreak. We are building Galidesivir as a broad-spectrum medical and biodefence countermeasure while concurrently undertaking the required initiatives for broader approval and believe maintaining a meaningful inventory of GMP-grade drug materially strengthens our ability to engage with governments, biodefence agencies and other potential partners around outbreak preparedness, procurement and stockpiling."

"Combined with our Marburg development program under the FDA's Animal Rule, our Ebola activities and the substantial body of work already completed on Galidesivir, we believe this expanded supply puts Island in a much stronger position to pursue the multiple development and commercial pathways now available to the asset."

Q&A

Why has Island commissioned a second GMP manufacturing campaign?

To materially expand available Galidesivir inventory so the company can respond to active outbreaks, support MEURI deployment and engage with governments without waiting for new manufacturing cycles.



How much Galidesivir will Island have available after this campaign?

Approximately 700–800 treatment courses are expected to be available in Q4 CY26.

Why is having increased GMP inventory strategically important?

Because outbreak response, government engagement and biodefence procurement all require immediate access to drug supply. Essentially, inventory equals capability.

Why manufacture now instead of waiting for pivotal data?

Because the Bundibugyo outbreak is accelerating rapidly, MEURI deployment is approved and governments act faster when a company already has deployable drug.

Who is manufacturing Galidesivir?

PI Health Sciences (PIHS), a global contract research, development and manufacturing organisation.

How severe is the current Bundibugyo Ebola outbreak?

As of 18 August 2026, 5,208 confirmed cases and 2,476 deaths — spreading five times faster than previous outbreaks at the same stage.

Why is Bundibugyo Ebola particularly dangerous?

It is highly transmissible, often misdiagnosed early and has “walking Ebola” characteristics. This means infected individuals can move through communities before detection.

Why is Galidesivir relevant to this outbreak?

Ebola Bundibugyo has no approved therapeutics or vaccines and Galidesivir is one of the few antivirals with strong primate efficacy across multiple filoviruses.

What efficacy data is available for Galidesivir in Ebola non-human primate models?

Galidesivir delivered 100% survival when treatment began 48 hours post-infection in the Ebola Zaire (Kikwit) NHP model and 67% survival even when dosing was delayed to 72 hours or administered without a loading dose. In all studies, every untreated control animal died, underscoring the strength of Galidesivir’s therapeutic effect.

Why is the Ebola NHP data important for Galidesivir’s regulatory and commercial pathway?

Alongside Marburg NHP data, Ebola NHP efficacy demonstrates that Galidesivir is a multi-filovirus countermeasure with clinically meaningful delayed-dosing windows. This strengthens the FDA Animal Rule package, supports future SNS procurement across multiple filovirus threats and reinforces Galidesivir’s relevance to the current Bundibugyo outbreak, where early detection is often impossible.



What is MEURI and why does it matter?

MEURI is a WHO emergency framework allowing investigational drugs to be used during outbreaks when no approved treatment exists; enabling generation of real human data.

When will Galidesivir be deployed under MEURI?

Deployment is expected during CY26, providing an opportunity to generate human efficacy, safety and virological data.

What is the FDA Animal Rule?

A specialised regulatory pathway allowing approval based on controlled non-human primate efficacy when human trials are not feasible.

Why is Galidesivir aligned with the Animal Rule?

Because it has demonstrated near-perfect survival in Marburg primate models and strong Ebola efficacy with delayed dosing.

What human data will MEURI provide?

Prospective clinical, safety and virological data in Bundibugyo Ebola patients. This is a rare and highly valuable dataset.

How do Animal Rule + MEURI complement each other?

Animal Rule provides controlled efficacy; MEURI provides real-world human data. Together they create a uniquely strong regulatory package.

What is the expected timeline to NDA submission?

NDA preparation begins Q3CY27, following pivotal Marburg Angola studies.

What is the significance of the Marburg NHP survival data?

Galidesivir achieved 94% survival even with treatment starting 48 hours post-infection. This is an exceptionally rare therapeutic window in filovirus models.

Why is the Angola strain important?

It is the FDA's standard model for Marburg approval under the Animal Rule. Island's pivotal studies will use this strain.

How does Galidesivir compare to untreated controls?

In both Marburg and Ebola studies, all untreated animals died, highlighting the strength of Galidesivir's efficacy.



Why is delayed dosing important?

Because real outbreaks rarely allow immediate treatment – efficacy shown with delayed dosing is critical for real-world deployment and use.

Does Galidesivir show multi-filovirus activity?

Yes, Galidesivir has demonstrated strong efficacy in Marburg & Ebola NHP studies and Sudan (in vitro).

What is the commercial value of Animal Rule approvals historically?

Animal Rule countermeasures have generated between US\$100m–US\$1.2bn in lifetime sales since 2012, averaging US\$625m.

Why is Marburg a major commercial opportunity?

A countermeasure for Marburg Virus remains the only Category A biothreat with no antiviral in the U.S. Strategic National Stockpile: a gap governments cannot tolerate.

How much has the U.S. government already spent trying to develop a Marburg antiviral?

Approximately US\$600m in grants to date, with no successful product.

What is the Priority Review Voucher (PRV) worth?

Historically ~US\$200m on the secondary market.

Why is Galidesivir likely to be stockpiled?

Galidesivir is likely to be stockpiled since every successful Animal Rule countermeasure that has received FDA approval, has been procured into the SNS and, Galidesivir fits the same pattern.

Why is Galidesivir considered a biodefence countermeasure?

Galidesivir addresses multiple filovirus threats, has strong efficacy and aligns with government biodefence procurement frameworks.

How does inventory strengthen government engagement?

Governments engage more seriously when a company already has deployable drug — inventory signals readiness.

Why is Galidesivir relevant beyond Ebola and Marburg?

Galidesivir has broad-spectrum activity across 20+ RNA viruses, including MERS, Zika, Yellow Fever and measles (in vitro).



How does Galidesivir fit into national-security planning?

Galidesivir provides antiviral protection for continuity-of-government personnel, frontline responders and essential infrastructure leaders.

What is Island's long-term strategy for Galidesivir?

To accelerate Galidesivir into a strong revenue generator for ILA shareholders as a broad-spectrum antiviral and biodefence countermeasure, supported by Animal Rule approval, MEURI human data and a substantial GMP inventory capable of rapid deployment.

- Ends -

Approved for release to the ASX by:

The Board of Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

ⁱ <https://www.bloomberg.com/news/articles/2026-08-20/congo-ebola-outbreak-spreads-beyond-ituri-as-cases-rise-in-north-kivu>

ⁱⁱ <https://www.reuters.com/business/healthcare-pharmaceuticals/why-congos-ebola-outbreak-is-spreading-faster-than-previous-epidemics-2026-08-05/>